Coya Therapeutics Applauds U.S. House of Representatives for Passing ACT for ALS
December 10, 2021 08:00 ET
|
Coya Therapeutics
HOUSTON, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc. (“Coya” or the “Company”), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous...
Coya Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA on COYA101 for the Treatment of Amyotrophic Lateral Sclerosis
November 16, 2021 08:00 ET
|
Coya Therapeutics
HOUSTON, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc. (“Coya”), a privately held clinical-stage biotechnology company developing first-in-class approaches utilizing autologous...
Coya Therapeutics Appoints Dr. Adrian Hepner as Chief Medical Officer and Dr. Greg MacMichael as Chief Technical Officer
November 01, 2021 08:00 ET
|
Coya Therapeutics
HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc. (“Coya”), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells...
Coya Therapeutics Appoints Gene Mack as Chief Financial Officer
October 12, 2021 08:00 ET
|
Coya Therapeutics
HOUSTON, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc. (Coya), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Treg)...
Coya Therapeutics to Participate at the LifeSci Partners Summer Symposium
July 14, 2021 08:00 ET
|
Coya Therapeutics
HOUSTON, July 14, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc. (Coya), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Treg)...
Coya Therapeutics Receives Orphan Drug Designation from the FDA for ALS001, an Autologous Treg Cell Therapy, for the Treatment of ALS
July 07, 2021 08:00 ET
|
Coya Therapeutics
Completed Phase 2a trial with full data release by end of summer 2021 HOUSTON, July 07, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc. (Coya), a clinical-stage biotechnology company developing...
Coya Therapeutics to Host Key Opinion Leader Webinar on ALS001 for the Treatment of Amyotrophic Lateral Sclerosis
June 02, 2021 08:00 ET
|
Coya Therapeutics
-Featuring Stanley H. Appel, M.D., internationally renowned researcher and neurologist--Webinar to be held Friday, June 11, 2021 at 11:30 a.m. ET- HOUSTON, June 02, 2021 (GLOBE NEWSWIRE) -- Coya...
Ann Lee, Ph.D., SVP at Bristol Myers Squibb, Joins Coya Therapeutics™ Board of Directors
June 01, 2021 07:30 ET
|
Coya Therapeutics
HOUSTON, June 01, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc. (Coya™), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells...
Coya Therapeutics™ Announces the Appointment of Anabella Villalobos, Ph.D. to its Board of Directors
May 25, 2021 07:00 ET
|
Coya Therapeutics
HOUSTON, May 25, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc. (Coya™), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Tregs)...
Coya Therapeutics to Present at the Oppenheimer Rare & Orphan Disease Summit
May 14, 2021 08:00 ET
|
Coya Therapeutics
HOUSTON, May 14, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc., (Coya), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Tregs)...